15 June 2020>: Clinical Research
Therapeutic Effect of Chemotherapy Cycle in Nasopharyngeal Carcinoma (NPC) Patients Who Developed Bone-Only Metastasis
Sikai Nong BCD , Xinbin Pan BCD , Kaihua Chen EF , Ye Li CD , Xiaodong Zhu AFG*DOI: 10.12659/MSM.922244
Med Sci Monit 2020; 26:e922244
Table 1 Characteristics of the patient population.
Variables | N (%) | |
---|---|---|
Age | >60 | 10 (17.2%) |
≤60 | 48 (82.8%) | |
Sex | Male | 52 (89.7%) |
Female | 6 (10.3%) | |
Karnofsky performance status | ≤80 | 10 (17.2%) |
>80 | 48 (82.8%) | |
Histology (WHO) | Type I/II | 18 (31.0%) |
Type III | 40 (69.0%) | |
T stage | T1–2 | 18 (31.0%) |
T3–4 | 40 (69.0%) | |
N stage | N0–1 | 10 (17.2%) |
N2–3 | 48 (82.8%) | |
Number of bone metastatic sites | 1 | 16 (27.6%) |
2 | 10 (17.2%) | |
3 | 7 (12.1%) | |
>3 | 25 (43.1%) | |
Nasopharyngeal radiotherapy | Yes | 33 (56.9%) |
No | 25 (43.1%) | |
Chemotherapy regimen | TPF | 51 (88.0%) |
PF | 1 (1.7%) | |
TP | 1 (1.7%) | |
Others | 5 (8.6%) | |
TPF – docetaxel, cisplatin and 5-fluorouracil; PF – cisplatin and 5-fluorouracil; TP – docetaxel and cisplatin. |